{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Overall response rate (ORR) per Central Adjudication Committee is the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).\n\nsCR:\n\n* No detectable myeloma cells in the bone marrow.\n* Normal free light chain ratio.\n* Absence of clonal cells in the bone marrow.\n\nCR:\n\n* Negative immunofixation on the serum and urine.\n* Disappearance of any soft tissue plasmacytomas.\n* Less than 5% plasma cells in the bone marrow.\n\nVGPR:\n\n* Serum and urine M-protein detectable by immunofixation but not on electrophoresis, or\n* At least a 90% reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours.\n\nPR:\n\n* At least a 50% reduction in serum M-protein.\n* Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours.\n* For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"populationDescription":"All treated participants in the Efficacy Evaluable population. Data not collected.","reportingStatus":"POSTED","timeFrame":"From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).","title":"Overall Response Rate (ORR) Per Central Adjudication Committee","type":"SECONDARY"}